Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 154 No. 3 (2024)

Use of unlicensed drugs in a Swiss Pediatric University Hospital and associated prescribing error rates – a retrospective observational study

DOI
https://doi.org/10.57187/s.3369
Cite this as:
Swiss Med Wkly. 2024;154:3369
Published
04.03.2024

Summary

AIMS OF THE STUDY: Unlicensed drugs are frequently used in paediatric care. To what extent they are prescribed in hospital care in Switzerland is unclear. Because prescribing errors seem to occur more frequently with unlicensed drugs, we aimed to assess the prevalence of unlicensed drug prescriptions in two study periods (2018 and 2019) at the University Children’s Hospital Zurich, compare these periods and investigate whether unlicensed drugs were more prone to prescribing errors than licensed drugs.

METHODS: We conducted a sub-analysis of a retrospective single-centre observational study and analysed 5,022 prescriptions for a total of 1,000 patients from 2018 and 2019 in paediatric general wards. The rate of unlicensed drugs, consisting of imported or formula drugs, was investigated. The prescriptions from 2019 were further analysed on prescribing errors to see whether errors occurred more often in unlicensed or licensed drug use.

RESULTS: Of all prescriptions, 10.8% were unlicensed drugs, with around half each being imported and formula drugs. Among all patients, 34% were prescribed at least one unlicensed drug. Younger paediatric patients were prescribed more unlicensed drugs than older paediatric patients (newborns: 15.8% of prescriptions, infants: 13.4%, children: 10.6%, adolescents: 7.1%). Ibuprofen suppositories, midazolam oral solution and gentamicin i.v. solution were the most frequently prescribed imported drugs. Macrogol powder, lisinopril oral suspension and potassium chloride i.v. solution were the most frequently prescribed formula drugs. The most common drug forms in unlicensed use were oral liquid forms and i.v. solutions. Unlicensed drugs had a significantly higher rate of prescribing errors than licensed drugs (31.6 errors per 100 prescriptions [95% CI: 26.1–37.0] versus 24.3 errors per 100 prescriptions [95% CI: 22.3–26.2], p = 0.024). In particular, formula drugs carried a higher risk (36.4 errors per 100 prescriptions, p = 0.012).

CONCLUSIONS: Unlicensed drugs are frequently prescribed in this paediatric hospital setting in Switzerland. Around every tenth prescription is an unlicensed drug. Because unlicensed drugs showed a significantly higher rate of prescribing errors, licensed drugs are favourable in terms of medication safety and should be prescribed whenever possible. If no licensed drug is available, imported drugs should be favoured over formula drugs due to lower prescribing error rates. To increase medication safety in paediatrics in Switzerland, efforts are necessary to increase the number of suitable licensed drug formulations for paediatric patients, including developing new innovative drug formulations for children.

References

  1. Federal Act on Medicinal Products and Medicinal Devices, 812.21 (2000).
  2. Aronson JK, Ferner RE. Unlicensed and off-label uses of medicines: definitions and clarification of terminology. Br J Clin Pharmacol. 2017;83(12):2615-25. Epub 20170926. doi: 10.1111/bcp.13394. PubMed PMID: 28779556; PubMed Central PMCID: PMC5698582. DOI: https://doi.org/10.1111/bcp.13394
  3. Neubert A, Wong IC, Bonifazi A, Catapano M, Felisi M, Baiardi P, et al. Defining off-label and unlicensed use of medicines for children: results of a Delphi survey. Pharmacol Res. 2008;58(5-6):316-22. Epub 20080918. doi: 10.1016/j.phrs.2008.09.007. PubMed PMID: 18852048. DOI: https://doi.org/10.1016/j.phrs.2008.09.007
  4. Gore R, Chugh PK, Tripathi CD, Lhamo Y, Gautam S. Pediatric Off-Label and Unlicensed Drug Use and Its Implications. Curr Clin Pharmacol. 2017;12(1):18–25. 10.2174/1574884712666170317161935 DOI: https://doi.org/10.2174/1574884712666170317161935
  5. Shuib W, Wu XY, Xiao F. Extent, reasons and consequences of off-labeled and unlicensed drug prescription in hospitalized children: a narrative review. World journal of pediatrics : WJP. 2021;17(4):341-54. Epub 20210602. doi: 10.1007/s12519-021-00430-3. PubMed PMID: 34080130. DOI: https://doi.org/10.1007/s12519-021-00430-3
  6. Camacho Arroyo MT, Rivas Paterna AB, Meneses Monroy A, Cabrera García L, Blázquez González P, Mancebo Salas N, et al. Off-label and unlicensed drug use in a pediatric intensive care unit of a tertiary care Spanish hospital. A descriptive study. Arch Argent Pediatr. 2023;121(1):e202102550. Epub 20221006. doi: 10.5546/aap.2021-02550.eng. PubMed PMID: 36194689. DOI: https://doi.org/10.5546/aap.2021-02550.eng
  7. Moulis F, Durrieu G, Lapeyre-Mestre M. Off-label and unlicensed drug use in children population. Therapie. 2018;73(2):135-49. Epub 20180216. doi: 10.1016/j.therap.2018.02.002. PubMed PMID: 29580614. DOI: https://doi.org/10.1016/j.therap.2018.02.002
  8. Teigen A, Wang S, Truong BT, Bjerknes K. Off-label and unlicensed medicines to hospitalised children in Norway. J Pharm Pharmacol. 2017;69(4):432-8. Epub 20160623. doi: 10.1111/jphp.12581. PubMed PMID: 27334565; PubMed Central PMCID: PMC5396330. DOI: https://doi.org/10.1111/jphp.12581
  9. Di Paolo ER, Stoetter H, Cotting J, Frey P, Gehri M, Beck-Popovic M, et al. Unlicensed and off-label drug use in a Swiss paediatric university hospital. Swiss Med Wkly. 2006 Apr;136(13-14):218–22. DOI: https://doi.org/10.4414/smw.2006.11275
  10. Vieira I, Sousa JJ, Vitorino C. Paediatric Medicines - Regulatory Drivers, Restraints, Opportunities and Challenges. J Pharm Sci. 2021 Apr;110(4):1545–56. 10.1016/j.xphs.2020.12.036 DOI: https://doi.org/10.1016/j.xphs.2020.12.036
  11. Miljković N, Batista A, Polidori P, Kohl S, Horák P. Results of EAHP's 2019 Medicines Shortages Survey. Eur J Hosp Pharm. 2020;27(4):202-8. Epub 20200529. doi: 10.1136/ejhpharm-2020-002341. PubMed PMID: 32471816; PubMed Central PMCID: PMC7335625. DOI: https://doi.org/10.1136/ejhpharm-2020-002341
  12. Blankart KE, Felder S. Do Medicine Shortages Reduce Access and Increase Pharmaceutical Expenditure? A Retrospective Analysis of Switzerland 2015-2020. Value Health. 2022 Jul;25(7):1124–32. 10.1016/j.jval.2021.12.017 DOI: https://doi.org/10.1016/j.jval.2021.12.017
  13. Agency EM. Evidence of harm from off-label or unlicensed medicines in children. London: EMA; 2004.
  14. Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr. 1999 Sep;88(9):965–8. 10.1080/08035259950168469 10.1111/j.1651-2227.1999.tb00191.x DOI: https://doi.org/10.1111/j.1651-2227.1999.tb00191.x
  15. Conroy S. Association between licence status and medication errors. Arch Dis Child. 2011;96(3):305-6. Epub 20101203. doi: 10.1136/adc.2010.191940. PubMed PMID: 21131639. DOI: https://doi.org/10.1136/adc.2010.191940
  16. Bellis JR, Kirkham JJ, Thiesen S, Conroy EJ, Bracken LE, Mannix HL, et al. Adverse drug reactions and off-label and unlicensed medicines in children: a nested case-control study of inpatients in a pediatric hospital. BMC Med. 2013;11:238. Epub 20131107. doi: 10.1186/1741-7015-11-238. PubMed PMID: 24229060; PubMed Central PMCID: PMC4231613. DOI: https://doi.org/10.1186/1741-7015-11-238
  17. Schrier L, Hadjipanayis A, Stiris T, Ross-Russell RI, Valiulis A, Turner MA, et al. Off-label use of medicines in neonates, infants, children, and adolescents: a joint policy statement by the European Academy of Paediatrics and the European society for Developmental Perinatal and Pediatric Pharmacology. Eur J Pediatr. 2020;179(5):839-47. Epub 20200103. doi: 10.1007/s00431-019-03556-9. PubMed PMID: 31897842. DOI: https://doi.org/10.1007/s00431-019-03556-9
  18. Bonati M, Jacqz-Aigrain E, Choonara I. Licensed medicines, off-label use or evidence-based. Which is most important? Arch Dis Child. 2017;102(1):53-4. Epub 20160817. doi: 10.1136/archdischild-2016-311527. PubMed PMID: 27535476. DOI: https://doi.org/10.1136/archdischild-2016-311527
  19. Tilen R, Panis D, Aeschbacher S, Sabine T, Meyer Zu Schwabedissen HE, Berger C. Development of the Swiss Database for dosing medicinal products in pediatrics. Eur J Pediatr. 2022;181(3):1221-31. Epub 20211105. doi: 10.1007/s00431-021-04304-8. PubMed PMID: 34739591; PubMed Central PMCID: PMC8897330. DOI: https://doi.org/10.1007/s00431-021-04304-8
  20. Higi L, Käser K, Wälti M, Grotzer M, Vonbach P. Description of a clinical decision support tool with integrated dose calculator for paediatrics. Eur J Pediatr. 2021;•••: 10.1007/s00431-021-04261-2 DOI: https://doi.org/10.1007/s00431-021-04261-2
  21. Satir AN, Pfiffner M, Meier CR, Caduff Good A. Prescribing errors in children: what is the impact of a computerized physician order entry? Eur J Pediatr. 2023 Jun;182(6):2567–75. 10.1007/s00431-023-04894-5 DOI: https://doi.org/10.1007/s00431-023-04894-5
  22. EMA. ICH E11 (R1) guideline on clinical investigation of medicinal products in the paediatric population 2017 [cited 2022 25.11.2022]. international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-1.pdf]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e11r1-guideline-clinical-investigation-medicinal-products-pediatric-population-revision-1_en.pdf
  23. Association PCNE. The PCNE CLassification V 9.1: Pharmaceutical Care Network Europe; 2020 [cited 2022 20.06.2022]. Classification for Drug related problems].
  24. Forrey RA, Pedersen CA, Schneider PJ. Interrater agreement with a standard scheme for classifying medication errors. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2007;64(2):8. doi: 10.2146/ajhp060109. PubMed PMID: 17215468. DOI: https://doi.org/10.2146/ajhp060109
  25. Kaisto H, Sepponen K, Lindell-Osuagwu L, Sankilampi U. Off-label and unlicensed medicine prescribing in university hospital paediatric wards in Finland: A prospective study. Br J Clin Pharmacol. 2023;n/a(n/a). Epub 20230330. doi: 10.1111/bcp.15729. PubMed PMID: 36998116. DOI: https://doi.org/10.1111/bcp.15729
  26. Organization WH. Medication safety in high-risk situations. World Health Organization; 2019.

Most read articles by the same author(s)